telomere dysfunction to predict clinical outcomes in cll
Published 6 years ago • 97 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:37
telomere length as a prognostic parameter in cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
1:52
evaluating surrogacy endpoints in cll clinical trials
-
1:56
the future of fixed-duration therapy in cll
-
12:46
fixed duration treatment strategies in cll
-
3:46
latest updates in the cll treatment landscape
-
2:37
why is early stage chronic lymphocytic leukemia treatment delayed?
-
3:14
understanding cll pathogenesis by assessing clonotypes
-
2:19
long-term management of cll for improved outcomes
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
1:00
using molecular features to determine appropriate treatment strategies for patients with cll
-
1:18
involving the patient in treatment decisions for cll
-
1:33
future advancements in the treatment of cll
-
0:53
the future of cll treatment
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
0:56
the current treatment landscape in cll
-
1:11
integrating mrd data into treatment decisions in cll
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
1:37
the importance of genomic testing in the diagnosis of cll
-
2:26
outcomes of ven-based regimens in cll/sll following intolerance or progression on covalent btki's
-
2:36
treatment approaches to cll with high-risk molecular features